Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
about
Management of patients with hepatic metastases from neuroendocrine tumorsImaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in developmentAssessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).The Challenges of Treating Paraganglioma Patients with (177)Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment ProtocolsTherapeutic strategies for neuroendocrine liver metastases.Radiation exposure to caregivers from patients undergoing common radionuclide therapies: a review.Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.(177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.Theranostics of Neuroendocrine Tumors.Comment on Campana et al.: radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.First Results and Experience with PRRT in South Africa.Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al
P2860
Q27008832-9D47027F-2814-4679-BD02-8A23457C89A3Q28083433-C63E770B-B237-47C6-9194-640C92C7A774Q34157391-EEEBBB11-B4E5-4D91-9423-89B367FEC8ABQ35941125-FA682D9C-7144-49A5-B618-9D1DA7ECEADAQ38255979-E4F3BE08-DAA4-43CD-B00E-01F9764BD0BFQ38272267-CE595738-8F08-4E03-9DA3-68EC69928C43Q38845060-B6121E5B-CC5D-4659-A481-74200C67A2DDQ38919414-F2B8526A-17C8-416A-B797-38CC7B4DE4D7Q40587447-F301C8C0-773B-46E2-BA11-011A7C5451F1Q49612068-AB158E06-D0E7-4812-B9BF-9B350CDA32C7Q54657574-F6B7D0C0-1D2B-4C1A-8943-C3F1CEF4856BQ55231659-C223A54C-85FF-4ED4-9E56-7C9E3F3B2874Q56975959-D8DA3800-197D-4B12-AFC2-BFF43BE0BEC0
P2860
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Radiolabelled somatostatin ana ...... ions for therapeutic sequence.
@en
Radiolabelled somatostatin ana ...... ions for therapeutic sequence.
@nl
type
label
Radiolabelled somatostatin ana ...... ions for therapeutic sequence.
@en
Radiolabelled somatostatin ana ...... ions for therapeutic sequence.
@nl
prefLabel
Radiolabelled somatostatin ana ...... ions for therapeutic sequence.
@en
Radiolabelled somatostatin ana ...... ions for therapeutic sequence.
@nl
P2093
P2860
P50
P1476
Radiolabelled somatostatin ana ...... ions for therapeutic sequence.
@en
P2093
Domenico Tamburrino
Francesca Nori
Gabriele Capurso
Gianfranco Delle Fave
Giulia Cacciari
Paola Tomassetti
P2860
P2888
P304
P356
10.1007/S00259-013-2402-2
P577
2013-04-26T00:00:00Z